{
  "trial_id": "NCT01008462",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "capacity to give informed consent",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "detectable tumor prior to mobilization regimen",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "patients with stored autologous stem cells will be allowed",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "stem cells from an identical donor could be used for autologous hematopoietic cell transplant (HCT)",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "marrow is the preferred source of stem cells from the HLA-haploidentical donor, however, peripheral blood mononuclear cells (PBMC) could be used as stem cell source",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "cross-over to other tandem autologous-allogeneic research protocol (#1409 or other appropriate protocol) will be allowed if a suitable HLA-matched related or unrelated donor is identified before receiving the allogeneic transplantation and if the patient meets the eligibility criteria of the subsequent study",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "cross-over from other tandem autologous-allogeneic research protocol (#1409 or other appropriate protocol) will be allowed if the patient loses the suitable HLA-matched related or unrelated donor but has an available HLA-haploidentical donor before receiving the allogeneic transplantation and if the patient meets the eligibility criteria of the subsequent study",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "lymphoma: patients with diagnosis of non-Hodgkin lymphoma (NHL) or Hodgkin's lymphoma (HL), of any histological grade",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "refractory or relapsed disease after standard chemotherapy",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "high risk of early relapse following autograft alone",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "waldenstrom's macroglobulinemia: must have failed 2 courses of therapy",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "cll: patients with either a diagnosis of t-cell cll or t-cell prolymphocytic leukemia (pll) who have failed initial chemotherapy, patients with t cell cll or pll or diagnosis of b-cell clll, b-cell small lymphocytic lymphoma, or b-cell cll that progressed to pll who either",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "life expectancy severely limited by disease other than malignancy",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "seropositive for the human immunodeficiency virus",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "female patients who are pregnant or breastfeeding",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "central nervous system (cns) involvement with disease refractory to intrathecal chemotherapy",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "notes": "64yo woman with multiple myeloma, s/p allogeneic transplant with recurrent disease and with systemic amyloidosis. On hemodialysis for ESRD.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT01008462",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}